100+ Free ABU Urology Practice Questions

Pass your ABU Urology Qualifying Examination (Part 1) exam on the first try — instant access, no signup required.

✓ No registration✓ No credit card✓ No hidden fees✓ Start practicing immediately

~85-90% first-time on the Qualifying Examination (ABU annual statistics) Pass Rate

100+ Questions

100% Free

1 / 100

Question 1

Score: 0/0

According to the 2018 USPSTF recommendation (still current in 2026), what is the recommended approach to PSA screening for prostate cancer in men aged 55-69?

Universal annual screening

Screening only after age 70

Individualized decision based on shared decision-making (Grade C)

Screening is contraindicated in this age group

to track

2026 Statistics

Key Facts: ABU Urology Exam

~300

Total MCQ Items

ABU Qualifying Examination (Part 1)

~8 hr

Total Exam Time

1-day computer-based test including breaks

~43%

Oncology Weight

Combined prostate, bladder/UT, kidney, testis, adrenal, penile

~$1,900

2026 Qualifying Fee

ABU (verify current schedule)

5 yr

Urology Residency

ACGME: PGY-1 intern + 4 years urology

~85-90%

First-Time Pass Rate

ABU annual statistics

The ABU Urology Qualifying Examination (Part 1) is a 1-day computer-based test from the American Board of Urology comprising ~300 single-best-answer MCQs over ~8 hours at Pearson VUE. Content spans prostate (~15%), kidney/testis/adrenal/penile (~14%), bladder and upper tract (~11%), pediatric (~10%), female urology (~8%), BPH/LUTS (~7%), stones (~6%), trauma (~6%), infections (~6%), ED/andrology (~4%+~4%), neurourology (~4%), and transplant (~2%). Qualifying Exam fee is ~$1,900; requires completion of an ACGME-accredited urology residency (5 years). Passing Part 1 is prerequisite to Part 2 (Certifying Oral) taken ~16 months post-residency.

Sample ABU Urology Practice Questions

Try these sample questions to test your ABU Urology exam readiness. Each question includes a detailed explanation. Start the interactive quiz above for the full 100+ question experience with AI tutoring.

1According to the 2018 USPSTF recommendation (still current in 2026), what is the recommended approach to PSA screening for prostate cancer in men aged 55-69?

A.Universal annual screening

B.Screening only after age 70

C.Individualized decision based on shared decision-making (Grade C)

D.Screening is contraindicated in this age group

Explanation: USPSTF 2018 gives a Grade C recommendation for PSA-based screening in men 55-69, advising shared decision-making that weighs potential benefits (reduced metastatic disease and prostate cancer mortality) against harms (overdiagnosis, overtreatment). For men 70+, USPSTF recommends against routine screening (Grade D). AUA 2023 guidelines similarly emphasize shared decision-making and support baseline PSA at age 45-50.

2On multiparametric prostate MRI, a PI-RADS v2.1 category 4 lesion indicates what?

A.Clinically significant cancer is very unlikely

B.Clinically significant cancer is likely

C.Clinically significant cancer is highly likely

D.Benign findings only

Explanation: PI-RADS v2.1: 1 = very low (clinically significant cancer very unlikely), 2 = low (unlikely), 3 = intermediate (equivocal), 4 = high (likely), 5 = very high (highly likely). PI-RADS 4 and 5 lesions warrant targeted biopsy (MRI-TRUS fusion or in-bore). PI-RADS 3 management is individualized using PSA density, prior biopsy history, and patient factors.

3A Gleason score of 3+4=7 corresponds to which ISUP/WHO Grade Group?

A.Grade Group 1

B.Grade Group 2

C.Grade Group 3

D.Grade Group 4

Explanation: ISUP Grade Groups: GG1 = Gleason ≤6 (3+3); GG2 = 3+4=7; GG3 = 4+3=7; GG4 = 8 (4+4, 3+5, 5+3); GG5 = 9-10. GG1 is favorable and commonly managed with active surveillance. GG2 may still be AS-eligible in selected low-volume cases per NCCN/AUA favorable intermediate-risk criteria.

4According to NCCN 2026 risk stratification for localized prostate cancer, which of the following defines HIGH-risk disease?

A.PSA <10, GG1, cT1c

B.PSA 10-20, GG2, cT2a

C.PSA >20 OR GG4-5 OR cT3a

D.Any PSA with cT1c and GG1

Explanation: NCCN high-risk localized prostate cancer: PSA >20 ng/mL, Grade Group 4-5 (Gleason 8-10), OR clinical stage T3a. Very-high-risk adds cT3b-T4, primary Gleason 5, >4 cores GG4-5, or 2-3 high-risk features. High-risk disease is treated with RP + pelvic LND or RT + long-term ADT (18-36 months), and PSMA-PET/CT is recommended for staging.

5PSMA-PET/CT is now the preferred initial staging modality in which scenario per 2026 NCCN guidelines?

A.All patients with PSA <4

B.Unfavorable intermediate-, high-, and very-high-risk prostate cancer at initial staging

C.Only for biochemical recurrence after surgery

D.Only in metastatic castration-resistant disease

Explanation: NCCN 2026 endorses PSMA-PET/CT (Ga-68 PSMA-11 or F-18 piflufolastat/flotufolastat) as a preferred first-line imaging modality for unfavorable intermediate-, high-, and very-high-risk prostate cancer staging, and for biochemical recurrence evaluation. It replaces the historical need for CT + bone scan in those settings due to superior sensitivity and specificity (proPSMA trial).

6A 58-year-old man has Grade Group 1 (Gleason 3+3) prostate cancer in 2 of 12 cores, PSA 5.2, cT1c, PSA density 0.12. What is the preferred management per AUA/ASTRO/SUO 2022 guidelines?

A.Radical prostatectomy

B.External beam radiotherapy with ADT

C.Active surveillance

D.Brachytherapy with ADT

Explanation: Active surveillance is the preferred (strong recommendation) management for low-risk (GG1) prostate cancer per AUA/ASTRO/SUO guidelines. Surveillance typically includes serial PSA (every 6 months), DRE, confirmatory mpMRI, repeat biopsy at 1-3 years, and optional genomic classifier (Decipher, Oncotype DX GPS, Prolaris) to refine risk.

7The VISION trial established which therapy for PSMA-positive metastatic castration-resistant prostate cancer after progression on ARPI and taxane chemotherapy?

A.Radium-223

B.Lutetium-177 PSMA-617 (177Lu-PSMA)

C.Sipuleucel-T

D.Cabazitaxel

Explanation: The VISION trial (NEJM 2021) randomized mCRPC patients who had progressed on at least one ARPI and one taxane to 177Lu-PSMA-617 + standard of care vs SOC alone. 177Lu-PSMA improved rPFS (8.7 vs 3.4 months) and OS (15.3 vs 11.3 months). It requires PSMA-PET positive disease for eligibility and is FDA-approved (Pluvicto).

8A patient with mCRPC has a germline BRCA2 mutation. Which targeted therapy is FDA-approved in this setting?

A.Pembrolizumab

B.Olaparib (PARP inhibitor)

C.Vemurafenib

D.Trastuzumab

Explanation: Olaparib (PROfound trial) and rucaparib (TRITON2) are PARP inhibitors approved for mCRPC with homologous recombination repair (HRR) gene mutations, including BRCA1/2, ATM, CHEK2, and others. Olaparib combined with abiraterone (PROpel) is also approved first-line in mCRPC with BRCA1/2 alterations. Germline/somatic genetic testing is recommended in all metastatic prostate cancer.

9Which of the following is an androgen receptor pathway inhibitor (ARPI) approved for nonmetastatic castration-resistant prostate cancer (nmCRPC)?

A.Sipuleucel-T

B.Darolutamide

C.Docetaxel

D.Radium-223

Explanation: Darolutamide (ARAMIS), apalutamide (SPARTAN), and enzalutamide (PROSPER) are all second-generation AR antagonists approved for nmCRPC with rapid PSA doubling time (≤10 months). All three improved metastasis-free survival and overall survival. Darolutamide has minimal CNS penetration and is often favored for seizure/fall risk patients.

10The ARASENS trial demonstrated an overall survival benefit for which triplet therapy in metastatic hormone-sensitive prostate cancer (mHSPC)?

A.ADT + bicalutamide + radium-223

B.ADT + docetaxel + darolutamide

C.ADT + sipuleucel-T + abiraterone

D.ADT alone

Explanation: ARASENS (NEJM 2022): ADT + docetaxel + darolutamide vs ADT + docetaxel + placebo in mHSPC. The triplet reduced death risk by 32.5% (HR 0.68). Similarly, PEACE-1 showed benefit with ADT + docetaxel + abiraterone. Triplet therapy is now a standard option for high-volume/high-risk mHSPC fit for chemotherapy.

About the ABU Urology Exam

The ABU Urology Qualifying Examination (Part 1) validates core knowledge for independent urologic practice. Content spans urologic oncology — prostate (PSA/USPSTF, PI-RADS v2.1, ISUP/NCCN, Decipher, PSMA-PET, VISION 177Lu-PSMA, ARASENS, PROpel/olaparib), bladder/upper tract (NMIBC BCG, KEYNOTE-057 pembrolizumab, Anktiva, MIBC neoadjuvant, CheckMate 274 adjuvant nivolumab, EV-302 enfortumab+pembro, POUT UTUC), kidney (KEYNOTE-564 adjuvant pembro, KEYNOTE-426, CheckMate 214/9ER, belzutifan VHL), testis (BEP/RPLND/markers), adrenal, penile — plus pediatric urology (cryptorchidism, hypospadias, VUR/RIVUR, PUV, UPJ), female urology and pelvic floor (SUI slings, POP, OAB — vibegron/mirabegron/botox/SNM, IC/BPS), BPH/LUTS (AUA 2023 — HoLEP, Rezum, UroLift, Aquablation, iTind, TURP), stone disease and endourology (AUA — URS/PCNL/SWL, thulium fiber laser), trauma (AAST renal/ureteral/bladder/urethral), infections (CDC 2021 STI, prostatitis NIH, Fournier's), ED and male andrology (PDE5, IPP, Peyronie's Xiaflex, testosterone therapy), infertility and reconstruction (microTESE, varicocele, urethroplasty, urinary diversion), neurourology (urodynamics, neurogenic bladder, autonomic dysreflexia), and renal transplantation. Requires completion of an ACGME-accredited urology residency (5 years).

Questions

300 scored questions

Time Limit

1-day CBT (~8 hours including breaks)

Passing Score

Criterion-referenced scaled score set by ABU (modified Angoff standard)

Exam Fee

~$1,900 Qualifying Examination fee (ABU 2026 — verify current schedule) (American Board of Urology (ABU) / Pearson VUE)

ABU Urology Exam Content Outline

~15%

Urologic Oncology — Prostate

PSA screening (USPSTF 2018 Grade C 55-69, Grade D 70+; AUA 2023 baseline 45-50), PI-RADS v2.1 (4 = likely, 5 = highly likely), transperineal vs transrectal biopsy, MRI-TRUS fusion, ISUP/WHO Grade Group (GG1-GG5), NCCN risk stratification, Decipher genomic classifier, PSMA-PET/CT staging and biochemical recurrence, active surveillance, radical prostatectomy, hypofractionated radiotherapy, mHSPC triplet therapy (ARASENS — darolutamide + ADT + docetaxel), PROpel (olaparib + abiraterone BRCA), VISION (177Lu-PSMA-617 mCRPC), TULSA, focal therapy.

~14%

Urologic Oncology — Kidney & Testis

Renal mass workup (CT/MRI, selective biopsy), small renal mass AS vs partial nephrectomy vs ablation, hereditary syndromes (VHL — belzutifan, BHD, HLRCC, TSC), adjuvant pembrolizumab (KEYNOTE-564), metastatic RCC IO combos (pembro+axi KEYNOTE-426, nivo+ipi CheckMate 214, nivo+cabo CheckMate 9ER). Testis: seminoma vs NSGCT markers (AFP, β-hCG, LDH), RPLND templates, BEP chemotherapy, stage I surveillance vs carboplatin for seminoma. Adrenal pheochromocytoma (alpha first) and aldosteronoma; penile SCC and inguinal lymphadenectomy.

~11%

Urologic Oncology — Bladder & Upper Tract

NMIBC AUA/SUO risk, TURBT with re-TURBT, BCG induction + SWOG maintenance, BCG-unresponsive (pembrolizumab KEYNOTE-057, Anktiva/nogapendekin + BCG, gemcitabine/docetaxel, nadofaragene firadenovec), MIBC neoadjuvant cisplatin (MVAC, gem-cis), radical cystectomy + PLND, trimodal bladder preservation, adjuvant nivolumab (CheckMate 274), metastatic first-line enfortumab vedotin + pembrolizumab (EV-302), erdafitinib FGFR3, UTUC (POUT adjuvant chemotherapy) and nephroureterectomy vs kidney-sparing with jelmyto.

~10%

Pediatric Urology

Cryptorchidism (orchiopexy 6-18 mo, Fowler-Stephens for intra-abdominal), hypospadias (MAGPI, TIP/Snodgrass), VUR grading I-V and RIVUR trial (prophylaxis for dilating reflux/febrile UTI), posterior urethral valves, UPJ obstruction (Anderson-Hynes pyeloplasty), hydronephrosis SFU/UTD, neurogenic bladder (spina bifida, CIC), prune belly, DSD (46,XX CAH 21-hydroxylase; 46,XY CAIS), Wilms (COG), neuroblastoma, enuresis (desmopressin/alarm), testicular torsion (bell-clapper).

~8%

Female Urology & Pelvic Floor

Stress urinary incontinence (midurethral sling — retropubic/transobturator/single-incision), urethral bulking, autologous fascial sling, urethral diverticulum, vesicovaginal fistula (transvesical vs Latzko), POP (POP-Q, sacrocolpopexy, native tissue, colpocleisis), mesh complications, overactive bladder (behavioral, antimuscarinics, vibegron/mirabegron, onabotulinumtoxinA 100 U, SNM, PTNS), interstitial cystitis/BPS (AUA stepwise), recurrent UTI prophylaxis.

~7%

BPH / LUTS

AUA 2023 BPH/LUTS guideline: IPSS, alpha-1 blockers (tamsulosin/silodosin/alfuzosin), 5-ARIs for prostate ≥30 mL, PDE5 tadalafil, combination therapy. Surgical options by prostate volume and morphology — HoLEP (size-independent), Rezum water vapor, UroLift PUL, Aquablation AquaBeam robotic waterjet, iTind temporary implant, prostatic artery embolization, simple prostatectomy or GreenLight for very large glands, TURP benchmark.

~6%

Stone Disease / Endourology

Stone composition (calcium oxalate most common, uric acid radiolucent, struvite triple phosphate, cystine hexagonal), metabolic workup (24-h urine), medical therapy (thiazide, K-citrate, allopurinol), dietary (fluid, DASH, normal calcium), MET with tamsulosin for distal ureteral 5-10 mm, low-dose NCCT, SWL vs URS vs PCNL per AUA (size/location/HU), stents, staghorn (PCNL first-line), supine vs prone PCNL, mini-PCNL, Thulium fiber laser vs Ho:YAG.

~6%

Trauma & Emergencies

Renal trauma (AAST I-V; CT with delayed-phase urography; NOM for stable blunt), ureteral injury (Boari flap, psoas hitch, ileal ureter), bladder rupture (intraperitoneal surgical; extraperitoneal catheter), urethral injury (posterior realignment vs delayed urethroplasty; straddle anterior), testicular rupture (exploration), Fournier's gangrene (emergent debridement), penile fracture (tunica repair), priapism (ischemic — aspiration/phenylephrine; nonischemic — embolization).

~6%

Infections & Inflammation

Uncomplicated cystitis (nitrofurantoin 5 d, TMP-SMX, fosfomycin single dose), pyelonephritis, complicated UTI, prostatitis (NIH I-IV; CP/CPPS), epididymo-orchitis, STIs per CDC 2021 (gonorrhea — ceftriaxone 500 mg IM; chlamydia — doxycycline; syphilis — benzathine penicillin G; HSV — acyclovir), GU tuberculosis, schistosomiasis and bladder SCC risk, emphysematous pyelonephritis, perinephric abscess, antibiotic stewardship, sepsis bundles.

~4%

Erectile Dysfunction

ED workup (IIEF, nocturnal tumescence, penile duplex), PDE5 inhibitors (sildenafil, tadalafil, vardenafil, avanafil — contraindicated with nitrates), intracavernosal alprostadil, MUSE, vacuum erection device, inflatable penile prosthesis (AMS 700, Titan), Peyronie's disease (collagenase clostridium histolyticum Xiaflex, Nesbit, plaque incision/grafting), low testosterone (AUA <300 ng/dL on two AM samples plus symptoms), testosterone monitoring (PSA, hematocrit).

~4%

Andrology / Male Infertility & Reconstruction

Male infertility workup (semen analysis ×2, FSH/LH/T/prolactin, karyotype, Y microdeletion, CFTR for CBAVD), varicocelectomy (subinguinal microsurgical), obstructive vs nonobstructive azoospermia, microTESE, vasectomy and reversal (vasovasostomy, vasoepididymostomy), urethral stricture (DVIU vs urethroplasty — anastomotic, buccal mucosa onlay), bladder neck contracture, urinary diversion (ileal conduit, Indiana pouch, neobladder — Studer, Hautmann), Mitrofanoff appendicovesicostomy.

~4%

Neurourology & Voiding Dysfunction

Neurogenic LUT dysfunction (SCI — autonomic dysreflexia above T6 requires immediate bladder decompression and antihypertensives; MS; Parkinson's; stroke; spina bifida), urodynamics (CMG, pressure-flow, EMG, video), detrusor overactivity, DSD, detrusor underactivity, AUS, bladder augmentation (ileocystoplasty; malignancy, perforation, metabolic acidosis risks), sacral neuromodulation (InterStim), PTNS, CIC, onabotulinumtoxinA 200 U for neurogenic DO.

~2%

Renal Transplantation

Donor evaluation (living vs deceased), HLA matching, immunosuppression (induction — basiliximab, ATG; maintenance — tacrolimus + MMF + prednisone; belatacept), rejection (hyperacute antibody-mediated, acute cellular, acute antibody-mediated, chronic), BK virus nephropathy, CMV, PTLD (EBV-driven), surgical complications (lymphocele, ureteral stricture, vascular thrombosis), recurrent disease (FSGS, IgA, aHUS), native nephrectomy indications (ADPKD, refractory hypertension).

How to Pass the ABU Urology Exam

What You Need to Know

Passing score: Criterion-referenced scaled score set by ABU (modified Angoff standard)
Exam length: 300 questions
Time limit: 1-day CBT (~8 hours including breaks)
Exam fee: ~$1,900 Qualifying Examination fee (ABU 2026 — verify current schedule)

Keys to Passing

Complete 500+ practice questions
Score 80%+ consistently before scheduling
Focus on highest-weighted sections
Use our AI tutor for tough concepts

ABU Urology Study Tips from Top Performers

1PI-RADS v2.1 pearls: 1 = very low (CS cancer very unlikely), 2 = low (unlikely), 3 = intermediate/equivocal, 4 = high (likely), 5 = very high (highly likely). PI-RADS 4 and 5 warrant targeted biopsy (MRI-TRUS fusion or in-bore). PI-RADS 3 is individualized using PSA density (≥0.15 ng/mL/cc favors biopsy), prior biopsy status, and patient factors. Transperineal biopsy has lower infection rates than transrectal and is increasingly first-line.

2Prostate cancer 2026 systemic therapy landmarks: mHSPC triplet therapy ARASENS — darolutamide + ADT + docetaxel (OS benefit). PROpel — olaparib + abiraterone in mCRPC with BRCA/HRR mutations (rPFS/OS benefit in BRCA-mutated). VISION — 177Lu-PSMA-617 for PSMA+ mCRPC post-ARPI/taxane. ARAMIS, SPARTAN, and PROSPER support ARPI in nmCRPC with PSA doubling ≤10 months.

3NMIBC BCG-unresponsive pathway: carcinoma in situ (or HG Ta/T1) persistent/recurrent after adequate BCG (≥5 of 6 induction + 2 of 3 maintenance OR 2 of 6 re-induction). Options: radical cystectomy (gold standard), pembrolizumab (KEYNOTE-057 FDA-approved for BCG-unresponsive CIS with or without papillary, CR ~41% at 3 months), Anktiva/nogapendekin alfa + BCG (FDA-approved 2024), nadofaragene firadenovec (intravesical gene therapy), gemcitabine+docetaxel sequential intravesical.

4AUA 2023 BPH/LUTS surgical options — match to prostate volume: <30 mL — PUL (UroLift) or Rezum; 30-80 mL — Rezum, UroLift (if no median lobe), PUL, TURP, HoLEP, Aquablation, iTind; 80-150 mL — HoLEP, Aquablation, simple prostatectomy, GreenLight; >150 mL — HoLEP (size-independent) or simple prostatectomy. UroLift preserves ejaculatory function; Aquablation is MRI-planned robotic waterjet with low sexual side-effect profile.

5Autonomic dysreflexia in SCI above T6: triggered by noxious stimulus below the level (full bladder most common, then bowel), causing sympathetic surge — severe hypertension, headache, flushing above lesion, bradycardia (reflex). Management: sit patient upright to drop BP, remove tight clothing, immediately drain the bladder (check catheter patency or straight catheterize; if occluded, replace), check for fecal impaction, use short-acting antihypertensive (nifedipine bite-and-swallow or nitrates) if SBP persistently elevated. Prevent with regular CIC schedule and bowel regimen.

Frequently Asked Questions

What is the ABU Urology Qualifying Examination?

The ABU Qualifying Examination (Part 1) is administered by the American Board of Urology and is the first of two required examinations for initial board certification in urology. It validates core knowledge across urologic oncology (prostate, bladder/upper tract, kidney, testis, adrenal, penile), pediatric urology, female urology and pelvic floor, BPH/LUTS, stone disease and endourology, trauma, infections, erectile dysfunction, andrology and infertility, reconstruction, neurourology, and renal transplantation. Passing Part 1 is required to become eligible for Part 2 (the Certifying Oral Examination).

Who is eligible to take the ABU Qualifying Examination?

Candidates must complete an ACGME-accredited urology residency (5 years — a PGY-1 intern year followed by 4 years of urology training) with program director attestation of satisfactory performance and ethics. A valid unrestricted medical license is required. After passing Part 1, candidates collect a 16-month post-residency case log and then take Part 2, the Certifying (Oral) Examination, to achieve initial certification.

What is the format of the ABU Qualifying Exam?

The Qualifying Examination is a 1-day computer-based test administered at Pearson VUE test centers, comprising approximately 300 single-best-answer multiple-choice items over roughly 8 hours including breaks. Items include clinical vignettes, imaging (CT, MRI, ultrasound, nuclear including PSMA-PET), and surgical and endoscopic photographs. The exam is blueprinted to the ABU content outline with urologic oncology comprising roughly 43% of items.

How much does the 2026 ABU Qualifying Exam cost?

The 2026 ABU Qualifying Examination fee is approximately $1,900 — always verify the current schedule on the ABU website. Candidates also pay a separate Certifying (Oral) Examination fee (~$2,000) at the Part 2 stage. Cancellation and refund policies follow the ABU schedule with decreasing refunds as the exam date approaches. Retakes require re-registration and full fee payment within the allowed qualification window.

When is the 2026 exam administered?

The ABU Qualifying Examination is typically offered once annually in the late summer. Applications generally open in the winter with a submission deadline several months before the test. Candidates schedule specific appointments with Pearson VUE after application approval. Exact 2026 dates and deadlines should be confirmed on the ABU examinations page.

How is the exam scored?

The ABU uses criterion-referenced scaled scoring with a passing standard set by subject-matter experts via the modified Angoff method. A candidate's pass/fail outcome depends on performance relative to the fixed cut-score, not on other candidates. Score reports include domain-level feedback. Candidates must pass Part 1 (Qualifying) before becoming eligible for Part 2 (Certifying Oral), which is taken approximately 16 months after residency with a case log.

What are the highest-yield topics?

Highest-yield topics include PI-RADS v2.1 and PSMA-PET interpretation, prostate cancer NCCN risk and ARASENS/PROpel/VISION updates, NMIBC BCG and BCG-unresponsive options (KEYNOTE-057 pembrolizumab, Anktiva), MIBC neoadjuvant chemotherapy and adjuvant nivolumab (CheckMate 274), mUC first-line EV-302 enfortumab+pembrolizumab, RCC adjuvant KEYNOTE-564 and IO combinations, testicular germ cell markers and BEP, AUA 2023 BPH (HoLEP/Rezum/UroLift/Aquablation/iTind), VUR/RIVUR, hypospadias and cryptorchidism, OAB (vibegron, botox, SNM), stone AUA guidelines (URS/PCNL/SWL), AAST trauma grading, CDC 2021 STI treatment, ED/IPP, Peyronie's Xiaflex, autonomic dysreflexia management, and transplant immunosuppression/rejection.

How should I study for this exam?

Use a structured 12-18 month plan layered on chief residency. Map to the ABU content outline: begin with urologic oncology (prostate, bladder, kidney, testis — the largest block at ~43%), then pediatric, female urology and pelvic floor, BPH, stones, trauma, infections, ED/andrology/infertility, neurourology, and transplant. Integrate Campbell-Walsh-Wein, AUA Update Series, AUA Core Curriculum, In-Service exam questions, and high-volume MCQ practice. Complete 2-3 full-length timed mock exams and drill imaging recognition (PI-RADS, PSMA-PET, CT urography) and endoscopic photograph interpretation.